Department of Pharmacology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, 1090 Vienna, Austria.
Int J Mol Sci. 2022 Dec 6;23(23):15440. doi: 10.3390/ijms232315440.
The field of targeted protein degradation (TPD) is a rapidly developing therapeutic modality with the promise to tame disease-relevant proteins in ways that are difficult or impossible to tackle with other strategies. While we move into the third decade of TPD, multiple degrader drugs have entered the stage of the clinic and many more are expected to follow. In this review, we provide an update on the most recent advances in the field of targeted degradation with insights into possible clinical implications for cancer prevention and treatment.
靶向蛋白降解(TPD)领域是一种快速发展的治疗模式,有望以其他策略难以或不可能实现的方式控制与疾病相关的蛋白质。虽然我们已经进入 TPD 的第三个十年,但已经有多种降解药物进入临床阶段,预计还会有更多的药物跟进。在这篇综述中,我们提供了靶向降解领域最新进展的最新信息,并深入探讨了其在癌症预防和治疗方面的可能临床意义。